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 HIF-1a is activated following myocardial
infarction, and is a critical transcription
factor promoting survival in hypoxia.
 Type 2 diabetes blunts HIF-1a activation
in ischemia and downstream adaptation to
hypoxia.
 This effect is mediated by increased long-
chain fatty acids, which prevent HIF-1a
activation in hypoxia.
 Succinate promotes HIF-1a activation by
inhibiting the regulatory HIF
hydroxylases. Fatty acids decrease
succinate concentrations in hypoxia, by
blocking increased glycolysis and malate-
aspartate shuttle activity.
 Pharmacologically activating HIF-1a or
increasing succinate concentrations
restores the hypoxic response and
improves functional recovery post-
ischemia in diabetes.https://doi.org/10.1016/j.jacbts.2018.04.005
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ABBR EV I A T I ON S
AND ACRONYMS
ANOVA = analysis of variance
BSA = bovine serum albumin
DMF = dimethyl fumarate
DMOG = dimethyloxalylglycine
FA = fatty acid
FIH = factor inhibiting hypoxia-
inducible factor
HIF = hypoxia-inducible factor
i.p. = intraperitoneal
IR = insulin resistance/resistant
MI = myocardial infarction
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reHypoxia-inducible factor (HIF)-1a is essential following a myocardial infarction (MI), and diabetic patients have
poorer prognosis post-MI. Could HIF-1a activation be abnormal in the diabetic heart, and could metabolism be
causing this? Diabetic hearts had decreased HIF-1a protein following ischemia, and insulin-resistant cardio-
myocytes had decreased HIF-1a-mediated signaling and adaptation to hypoxia. This was due to elevated fatty
acid (FA) metabolism preventing HIF-1a protein stabilization. FAs exerted their effect by decreasing succinate
concentrations, a HIF-1a activator that inhibits the regulatory HIF hydroxylase enzymes. In vivo and in vitro
pharmacological HIF hydroxylase inhibition restored HIF-1a accumulation and improved post-ischemic func-
tional recovery in diabetes. (J Am Coll Cardiol Basic Trans Science 2018;3:485–98) © 2018 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).A ctivation of hypoxic signalingpathways through stabilization ofhypoxia-inducible factor (HIF)-1a is
vital for cardiac survival in hypoxia, as occurspost-myocardial infarction (MI) or in heart failure
(1,2). In normoxia, HIF-1a protein is hydroxylated by
the oxygen-sensing HIF hydroxylase enzymes: prolyl
hydroxylase domain (PHD) and factor inhibiting HIF
(FIH), thereby targeting HIF-1a for proteasomal degra-
dation (3). During hypoxia, reduced oxygen availabil-
ity inhibits these HIF hydroxylase enzymes, leading to
HIF-1a protein accumulation, which can translocate to
the nucleus, bind to HIF1b, and induce transcription
of HIF target genes. HIF-1a has many hundreds of
gene targets, and broadly, these targets up-regulate
oxygen sparing pathways, down-regulate oxygen
consuming pathways, and increase oxygen delivery
(4–7). HIF-1a adapts metabolism to the oxygen-
restricted environment, increasing anaerobic glycol-
ysis while decreasing fatty acid (FA) oxidation and
mitochondrial respiration. HIF-1a plays a critical role
in the cellular response to hypoxia in many cardiovas-
cular diseases (1,2,8–10), and decreased HIF-1a activa-
tion accelerates the progression into heart failure in
genetic mouse models (1).SEE PAGE 499Cardiovascular disease is the leading cause of
mortality in type 2 diabetic patients, with poorer
long-term prognosis following MI and higher inci-
dence of heart failure (11–13). Impaired cardiacrsity of Oxford. The authors have reported that they have no r
test they are in compliance with human studies committees
Food and Drug Administration guidelines, including patient co
ic to Translational Science author instructions page.
ceived March 6, 2018; revised manuscript received April 23, 20function post-ischemia has been associated with
abnormal cardiac FA metabolism in diabetes. FAs are
the predominant fuel used by the heart to power
contraction, accounting for 60% to 70% of cardiac
ATP generation. In diabetes, FA oxidation and storage
are up-regulated, and lipid intermediates accumulate
within the myocardium (14,15). We have shown that
type 2 diabetes blunts the normal metabolic adapta-
tion to hypoxia, resulting in impaired cardiac func-
tion (16). However, the explanation for why hypoxic
adaption is blunted in diabetes and the underlying
mechanisms require investigation, as these may
explain why diabetic patients have poorer long-term
prognosis following MI and in heart failure. We
questioned whether abnormal FA metabolism could
drive abnormal HIF-1a activation and downstream
adaptation to hypoxia in diabetes.
Here, we show that type 2 diabetic hearts fail to
accumulate HIF-1a protein during ischemia, and this
is due to elevated FAs. FAs exert their effects by
decreasing succinate concentrations, an inhibitor of
the HIF hydroxylase enzymes, and supplementing
succinate restores HIF-1a accumulation in insulin
resistance (IR). Finally, we demonstrate that in vivo
HIF hydroxylase inhibition improves post-ischemic
recovery in diabetic rats.
METHODS
ANIMALS. All animal experiments conformed to the
Home Ofﬁce Guidance on the Operation of the An-
imals (Scientiﬁc Procedures) Act, 1986, and wereelationships relevant to the contents of this paper to
and animal welfare regulations of the authors’ in-
nsent where appropriate. For more information, visit
18, accepted April 24, 2018.
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487approved by the local ethics committee. Type 2
diabetes was induced as previously described
(17,18), generating a mild model of the disease
presenting with hyperglycemia, hyperinsulinemia,
and hyperlipidemia (19). Brieﬂy, male Wistar rats
were fed a high-fat diet ad libitum for 30 days, and
on the 14th day, rats received a single low-dose,
intraperitoneal (i.p.) injection of streptozotocin (25
mg ∙ kg-1 body weight, w/w in citrate buffer). On
day 30, rats were terminally anesthetized using a
0.7-ml i.p. injection of pentobarbital sodium (200
mg/ml Euthatal, Merial Animal Health/Boehringer
Ingelheim, Ingelheim, Germany). Blood glucose
concentrations was signiﬁcantly increased from 8.7
 0.4 mmol/l in control rats to 10.8  0.5 mmol/l in
diabetic rats. Hearts were removed and perfused,
according to our published protocol (20), in retro-
grade Langendorff mode at 100 mm Hg constant
pressure. Hearts were perfused with Krebs-
Henseleit buffer containing 11 mmol/l glucose, 0.3
U ∙ l1 insulin and 1.5% (w/v) FA-free bovine serum
albumin (BSA) bound to 0.4 mmol/l palmitate
(gassed with 95% O2 and 5% CO2, at 37C). Cardiac
function was measured using a polyvinyl chloride
balloon inserted into the left ventricle, with rate-
pressure product calculated as the multiple of
heart rate and developed pressure. Hearts were
perfused for 20 min at normal ﬂow, followed by 25
min of low-ﬂow ischemia (0.3 ml/min/gww). At the
end of ischemia, hearts were freeze clamped on the
cannula for tissue analysis.
For long-term in vivo dimethyloxalylglycine
(DMOG) treatment of diabetic rats, on the penulti-
mate week of high-fat feeding, animals were injected
i.p. with DMOG (40 mg/kg) every other day over 5
days (totaling 3 injections). After these 5 days of pre-
treatment, hearts were perfused for 20 min at normal
ﬂow, challenged with 30 min of low-ﬂow ischemia,
followed by 15 min of reperfusion, for assessment of
post-ischemic contractile recovery.
CELL CULTURE. HL-1 murine cardiomyocytes were
cultured as previously described (21), and all experi-
ments were performed on conﬂuent, beating cells. For
induction of IR, cells were washed twice with warm
phosphate-buffered saline, before the addition of
either control medium (Dulbecco’s Modiﬁed Eagles’
Medium) containing 1 g/l glucose, 2 mmol/l glutamine,
2 mmol/l nonessential amino acids, and 1 penicillin/
streptomycin) or IR medium (control medium sup-
plemented with 500 mmol/l palmitate:BSA [bound 6:1]
with 50 nmol/l insulin) (22,23). After 8 h, this medium
was replenished, and cells were either maintained in
normoxia or transferred into a hypoxic incubator (2%
O2, 5% CO2) for a further 16 h. In speciﬁc experiments,control medium was supplemented with only FAs
(either oleate or palmitate at concentrations from 150
to 500 mmol/l bound to BSA) or with only insulin (50
nmol/l). In other experiments, compoundswere added
to the media immediately before the cells entered
hypoxia for 16 h, which included 1 mmol/l DMOG, 100
mmol/l to 1 mmol/l dimethyl fumarate (DMF), 0.4
mmol/l sulfo-N-succinimidyl oleate (SSO), 5 mmol/l 2-
deoxyglucose, 2 mmol/l phenylsuccinate, 2 mmol/l
amino-oxyacetate, and 5 mmol/l dimethylmalonate.
The cell-permeable fumarate ester, dimethyl fuma-
rate, was used to elevate intracellular succinate levels,
because this has been shown to be more efﬁcient/cell
permeable than the succinate ester, dimethyl succi-
nate (24). For experiments that inhibited HIF degra-
dation, the proteasomal inhibitor MG132 (25 mmol/l)
was added, and cells were maintained in hypoxia for
4 h rather than 16 h, due to toxicity effects.
WESTERN BLOTTING. Cells were washed twice with
ice-cold phosphate-buffered saline, before being
lysed with the addition of ice-cold lysis buffer. Frozen
heart tissue was crushed and lysed in ice-cold lysis
buffer. Protein (9 mg for cells and 30 mg for tissue) was
loaded onto SDS-PAGE gels and separated by elec-
trophoresis. Even protein loading and transfer were
conﬁrmed by either the loading control b-actin or
Ponceau S staining. Bands were quantiﬁed using LI-
COR C-Digit chemiluminescent detection system (LI-
COR Biotechnology, Lincoln, Nebraska) and Image
Studio software version 5.2.5 (LI-COR).
QUANTITATIVE REAL-TIME POLYMERASE CHAIN
REACTION. Total RNA was extracted from cells using
mini-RNeasy kit (Qiagen, Hilden, Germany), and
cDNA was synthesized from the RNA using a
high-capacity RNA-to-cDNA kit (Thermo Fisher Sci-
entiﬁc, Waltham, Massachusetts). Primers were
generated by searching PrimerBank for accession
numbers of the following genes: Fih-1 NM_176958.3,
Hif1A NM_001313919, Hif1B NM_001037737.2,
Hprt1 NM_013556.2, Hmbs NM_001110251.1, Phd2
NM_053207.2, Phd3 NM_028133.2, Rpl13A
NM_173340.2, and vhl NM_009507.3 (PrimerBlast was
used to check speciﬁcity, and sequences are listed in
Supplemental Table 1). Phd1 is expressed at low
levels in the heart, and could not be reliably
measured (9). cDNA (15 mg per well) were loaded and
quantitative polymerase chain reaction ampliﬁcation
was performed using Power SYBR Green PCR Master
Mix and a Step-One Plus Real-Time PCR system
(Thermo Fisher Scientiﬁc, Waltham, Massachusetts).
Relative gene expression was normalized to the
geometric mean of the housekeeping genes: Rpl13a,
Hmbs, and Hrpt1.
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vested from ﬂasks with 0.05% trypsin-EDTA at 37C
and counted (using a Countess 1, Thermo Fisher Sci-
entiﬁc), and experiments were normalized to viable
cell number, expressed per million cells. Respiration
was measured using a Clark-type oxygen electrode in
medium (100 mmol/l potassium chloride, 50 mmol/l
MOPS, 1 mmol/l EGTA, 5 mmol/l potassium phos-
phate, and 1 mg/ml BSA) (25), supplemented with
palmitate (500 mmol/l bound to BSA) and malate (2.5
mmol/l) as substrates. Carbonyl cyanide p-tri-
ﬂuoromethoxyphenylhydrazone (FCCP) (10 mmol/l)
was used to measure maximal rates of oxygen con-
sumption, and oligomycin (2 mmol/l) was used to
measure ATP synthase-independent proton leak.
OIL-RED-O. Cells were washed and ﬁxed with 4%
paraformaldehyde, before being stainedwith oil-red-O
(for neutral lipids) and DAPI (for nuclei) as described
(26). Quantiﬁcation was performed by eluting the
oil-red-O in 100% isopropanol and measuring absor-
bance at 492 nm. To account for cell number, absor-
bance was normalized to protein content using a
bicinchoninic acid assay.
MEDIA METABOLITE MEASUREMENTS. An ABX Pen-
tra 400 (Horiba ABX Diagnostics, Irvine, California)
was used to measure media glucose and lactate con-
centrations, and to calculate glucose consumption
and lactate efﬂux rates. Plasma nonesteriﬁed fatty
acids (NEFA) were measured using a Randox NEFA kit
(Randox Laboratories, Crumlin, County Antrim,
United Kingdom).
METABOLOMIC ANALYSIS. Metabolites were extrac-
ted from frozen cardiac tissue using methanol–chlo-
roform–water, and the aqueous phase was analyzed
as previously described using liquid chromatography
tandem-mass spectrometry (19). Glycolytic and Krebs
cycle metabolites were semiquantitatively assessed,
by normalizing the peak intensity to a number of in-
ternal standards. Succinate concentrations were
measured in cells using a colorimetric assay (Abcam,
Cambridge, United Kingdom), normalized to protein.
STATISTICS. Results are presented as mean  SEM
(Figures 1 to 6). GraphPad Prism version 7 (GraphPad
Software, La Jolla, California) was used for statistical
tests, and results were considered signiﬁcant at p <
0.05. Depending on the experiment, either Student’s
unpaired t-test (Figures 1, 3, and 5), 1-way analysis of
variance (ANOVA) (Figures 4 to 6), or 2-way ANOVA
(Figures 2 to 4) were performed. Pearson correlations
were used for Figures 1 and 5. For the ANOVA analysis,
where statistical signiﬁcances between groups were
observed, a Tukey post hoc comparison was per-
formed and corrected for multiple comparisons.RESULTS
TYPE 2 DIABETIC HEARTS FAIL TO ACCUMULATE
HIF-1a DURING ISCHEMIA. Hearts from type 2 dia-
betic and control rats were subjected to 25 min of low-
ﬂow ischemia (Figure 1), and at the end of ischemia
accumulation of HIF-1a protein was measured. HIF-1a
protein levels were 21% lower in diabetic hearts
challenged with ischemia compared with control
hearts. The decreased HIF-1a accumulation was in-
dependent of any change in HIF1b protein levels.
There was a 96% increase in plasma NEFA concen-
trations in diabetic rats, which correlated negatively
with ischemic HIF-1a protein levels. HIF-1a in pre-
ischemia/normoxia was similarly absent in both
control and diabetic hearts (Figure 1), in agreement
with previous ﬁndings (16).
IR CARDIOMYOCYTES HAVE BLUNTED METABOLIC
ADAPTATION TO HYPOXIA. To investigate mecha-
nistically why diabetes suppresses cardiac HIF-1a
activation, an IR cardiac cell culture model was used
(22,23) (Supplemental Figure 1). Control HL-1 car-
diomyocytes exposed to 16 h of hypoxia exhibited the
hallmarks of the hypoxic metabolic shift from oxida-
tive to anaerobic metabolism, increasing lactate
efﬂux by 132%, increasing glucose consumption by
81%, and decreasing maximal respiration rates by 33%
(Figure 2). By contrast, these hypoxia-mediated
metabolic responses were all blunted in IR cells,
which failed to increase lactate efﬂux and glucose
consumption. IR cells did not reduce maximal respi-
ration following hypoxia, and instead increased ATP
synthase-independent proton leak by 38%. In addi-
tion, hypoxia further increased intracellular lipid
accumulation in the IR cardiomyocytes.
IR IMPAIRS HIF-1a ACCUMULATION AND DOWNSTREAM
SIGNALING IN HYPOXIA. HIF-1a protein levels were
minimal in control and IR cells cultured in normoxia
(Figure 3), in agreement with previous ﬁndings (16).
In control cells, hypoxia caused an w23-fold increase
in HIF-1a protein levels, causing downstream targets
of HIF (GLUT1 and cyclophilin B) to be increased,
GLUT1 increased 3-fold, and cyclophilin B increased
by 67% (6,27). By contrast, IR cells failed to accumu-
late HIF-1a protein in hypoxia, and downstream
metabolic HIF targets, GLUT1, and cyclophilin B, did
not increase in hypoxic IR cardiomyocytes. Whereas
IR cells were unable to activate HIF-1a signaling
during hypoxia, there was activation of the hypoxia-
sensitive activating transcription factor ATF1 (28).
Phosphorylated-ATF1 (pATF1) was elevated by hyp-
oxia, in both the controls and IR cells. This demon-
strates that IR selectively impairs hypoxic signaling
through HIF-1a protein.
FIGURE 1 Type 2 Diabetes Decreases HIF-1a Accumulation in Ischemia
(A) Cardiac function in control and diabetic rat hearts, at normal ﬂow and during ischemia (n ¼ 5 per group). (B and C) HIF-1a and HIF-1b
protein levels in ischemic control and diabetic hearts. (D and E) Non-esteriﬁed fatty acid (NEFA) plasma concentrations in control (Con) and
diabetic (Db) rats correlated with ischemic HIF-1a protein accumulation. HIF-1a protein in pre-ischemic control and diabetic hearts was
minimal, and is shown adjacent to a positive control (hypoxic cells) and rainbow marker (Rb). *p < 0.05 versus control. A.U. ¼ arbitrary units.
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FIGURE 2 IR Cardiomyocytes Are Unable to Metabolically Adapt to Hypoxia
(A and B) Lactate release and glucose consumption during normoxia and hypoxia in control and insulin-resistant (IR) HL-1 cardiomyocytes.
(C and D) Mitochondrial respiration following normoxia and hypoxia in control and insulin resistant cardiomyocytes, measured with FCCP to
maximally stimulate respiration or with oligomycin to block ATP synthase activity. (E) Staining for neutral lipids using oil-red-O following
normoxia and hypoxia in control and IR cardiomyocytes (normalized to normoxic control). *p < 0.05 versus normoxic control, #p < 0.05
versus normoxic insulin resistant, $p < 0.05 versus hypoxic control. Abs ¼ absorbance.
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490We investigated whether components of the HIF
signaling pathway were changed in the IR cells, which
would account for the lack of HIF-1a protein stabili-
zation in hypoxia. There was no difference in Hif1A
mRNA expression between control and IR cells
(Figure 3, Supplemental Figure 2). Components of the
HIF regulatory pathway did not differ between IR and
control cells in normoxia, including HIF-1a hetero-
dimer partner Hif1B, the oxygen-sensing enzymes
prolyl hydroxylase 2 (Phd2) and asparaginyl hydrox-
ylase factor inhibiting HIF (Fih), and the von Hippel-
Lindau (vhl)-E3 ubiquitin ligase that targets HIF-1a
protein for proteasomal degradation. Phd3mRNA wasdecreased in IR cells, but this would be predicted to
increase HIF-1a protein in hypoxia, not decrease it as
observed in the IR cells.
FAs PREVENT HIF-1a ACCUMULATION IN HYPOXIA
IN A CONCENTRATION-DEPENDENT MANNER. IR
was induced in our cells by a combination of hyper-
lipidemia and hyperinsulinemia. The component
responsible for impaired HIF-1a activation was
investigated by treating cells with either 50 nmol/l
insulin or 500 mmol/l palmitate. Hyperinsulinemia
alone did not affect HIF-1a activation or the
metabolic response to hypoxia (Figure 4). By contrast,
hyperlipidemia suppressed HIF-1a accumulation in
FIGURE 3 IR Impairs HIF-1a Protein Accumulation and Downstream Signaling
(A to C) HIF-1a protein accumulation and downstream targets GLUT1 and cyclophilin B protein levels following normoxia and hypoxia, in
control and insulin resistant cardiomyocytes. (D) Hypoxia-sensitive phospho-activating transcription factor (pATF) 1 protein levels following
normoxia and hypoxia, in control and insulin-resistant (IR) cardiomyocytes. (E and F) mRNA expression of Hif1A, Hif1B, prolyl hydroxylase
domain enzymes (Phd) 2 and 3, factor inhibiting HIF (Fih), and von-Hippel Lindau (vhl), in normoxic control and insulin resistant car-
diomyocytes. *p < 0.05 versus normoxic control, #p < 0.05 versus normoxic insulin resistant, $p < 0.05 versus hypoxic control,Jp < 0.05
versus effect of oxygen at 2-way analysis of variance. A.U. ¼ arbitrary units.
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1a to levels seen in IR cells. In addition, palmitate
decreased the downstream HIF-mediated metabolic
effects during hypoxia, decreasing lactate efﬂux,reducing glucose consumption and increasing lipid
accumulation in hypoxia. To investigate whether
changes were dependent on the concentration or
saturation of the FA, cells were incubated with 150,
FIGURE 4 FAs Prevent HIF-1a Accumulation in Hypoxia
(A to D) HIF-1a protein levels, lactate release, glucose consumption, and neutral lipid oil-red-O staining in normoxia and hypoxia in HL-1
cardiomyocytes cultured in control medium, insulin-resistant medium, and the 2 components that comprise the insulin-resistant medium:
high insulin (50 nmol/l) and high palmitate (500 mmol/l). (E and F) HIF-1a protein levels and lactate release in hypoxic cells cultured in
control medium (HC), insulin-resistant medium (HIR), and control medium supplemented with increasing concentrations of fatty acids (FAs)
palmitate or oleate (bound to BSA). (E) HIF-1a protein in hypoxic insulin-resistant cells when FA uptake was blocked with sulfo-N-suc-
cinimidyl oleate (SSO), immediately before the onset of hypoxia (HIRþSSO). *p < 0.05 versus respective normoxic group, $p < 0.05 versus
hypoxic control. A.U. ¼ arbitrary units.
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FIGURE 5 Elevated FAs in IR Decrease Hypoxic Succinate Concentrations Required for HIF-1a Stabilization
(A) HIF-1a protein levels following acute hypoxia in control (HC) and IR (HIR) HL-1 cardiomyocytes with the proteasome inhibitor MG132. (B)
HIF-1a protein levels in hypoxic IR cells with or without the HIF hydroxylase inhibitor dimethyloxalylglycine (DMOG). (C) In ischemic perfused
hearts, HIF-1a protein levels correlate positively with myocardial succinate levels. (D) Succinate concentrations following hypoxia in cells
cultured in control medium (HC), IR medium (HIR), and control medium supplemented with 500 mmol/l palmitate (HPal) or 500 mmol/l
oleate (HOle). (E and F) HIF-1a protein levels and succinate concentrations in hypoxic cells in the presence of the glycolysis inhibitor 2-
deoxyglucose (2DG), the malate-aspartate shuttle inhibitors phenylsuccinate and amino-oxyacetate (PS and AOA), and the succinate de-
hydrogenase inhibitor dimethylmalonate (DMM). (G and H) HIF-1a protein levels and succinate concentrations in hypoxia in IR cells, with or
without the cell permeable succinate donor dimethyl fumarate (DMF). *p < 0.05 versus hypoxic control, #p < 0.05 versus hypoxic insulin
resistant. Abbreviations as in Figure 4.
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FIGURE 6 Improved Post-Ischemic Recovery in Type 2
Diabetic Rats Following in Vivo HIF Hydroxylase Inhibition
Cardiac function (rate-pressure product) in control, type 2
diabetic and in vivo DMOG-treated type 2 diabetic rats, at
normal ﬂow, during ischemia, and following reperfusion (n ¼ 5
per group). *p < 0.05 versus control, $p < 0.05 versus
diabetic.
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abundant FAs in blood (29). The inhibition of HIF-1a
accumulation in hypoxia was proportional to the
concentration of FA, and to the same extent whether
palmitate or oleate were used. Consistent with the
reduced HIF-1a accumulation, there was a failure to
increase glycolytic lactate efﬂux with FA concentra-
tions of 350 mmol/l and above. Finally, we added the
sarcolemmal FA uptake inhibitor, SSO, to IR cells
immediately prior to hypoxia. Blocking sarcolemmal
fat uptake during hypoxia restored HIF-1a accumu-
lation (Figure 4), despite cells remaining IR
(Supplemental Figure 1).
ELEVATED FAs DECREASE SUCCINATE CONCENTRATIONS,
WHICH IS REQUIRED FOR HIF-1a ACCUMULATION. To
prevent HIF-1a degradation, we inhibited the pro-
teasome with MG132 in IR cells, and found thatproteasome inhibition restored HIF-1a to control
hypoxic levels (Figure 5), demonstrating the
FA-induced defect was due to increased HIF-1a tar-
geting for degradation during hypoxia. HIF-1a is
targeted for degradation by the HIF hydroxylases,
which are inhibited by low concentrations of oxy-
gen. Pharmacologically inhibiting these HIF hy-
droxylases using DMOG during hypoxia signiﬁcantly
increased HIF-1a accumulation in IR cells. Taken
together, this demonstrates that in IR, HIF-1a is be-
ing incorrectly targeted by the HIF hydroxylases for
proteasomal degradation, which should be inhibited
in hypoxia.
In cancer cells, in addition to low oxygen, HIF
hydroxylases have also been shown to be inhibited
by increased succinate concentrations, the product of
their hydroxylation reaction (24,30). Returning to our
ischemic hearts, myocardial levels of succinate
correlated positively with HIF-1a accumulation (con-
trol succinate 0.39  0.02, diabetic succinate 0.33 
0.03; p < 0.06) (Figure 5, Supplemental Table 2).
In the hypoxic IR cells succinate concentrations were
decreased by 24% compared with hypoxic controls,
which could be replicated by culturing hypoxic cells
with palmitate or oleate.
Succinate could be derived from the malate-
aspartate shuttle utilizing glycolytic NADH, coupled
to reverse Krebs cycle and succinate dehydrogenase
activity (31). To investigate whether this pathway was
responsible for regulating HIF-1a stabilization in hyp-
oxia, we pharmacologically inhibited multiple steps in
this pathway. In hypoxia, inhibition of glycolysis using
2-deoxyglucose, inhibition of the malate-aspartate
shuttle using phenylsuccinate or amino-oxyacetate,
or inhibition of succinate dehydrogenase all
decreased HIF-1a stabilization to a similar extent.
Thus, in hypoxia, succinate is derived from glycolysis
drivingmalate-aspartate shuttle activity. FAs interfere
with this process by suppressing glycolysis (Figure 4)
and decreasing succinate concentrations (Figure 5).
Culturing with the cell-permeable succinate donor,
DMF (24), increased succinate concentrations in hyp-
oxic IR cells. In addition, succinate supplementation
with DMF increasedHIF-1a accumulation in hypoxic IR
cells in a concentration-dependent manner, and at 1
mmol/l DMF to the same level as DMOG. Increasing
succinate restored HIF-1a accumulation in IR, over-
riding the inhibitory effects of FAs.
IN VIVO HIF HYDROXYLASE INHIBITION IS ABLE TO
IMPROVE POST-ISCHEMIC RECOVERY IN TYPE 2
DIABETES. Finally, we questioned whether in vivo
HIF hydroxylase inhibition could provide a
FIGURE 7 Schematic Detailing the Proposed Mechanism for HIF-1a Suppression
in Diabetes
In control cells, hypoxia drives increased anaerobic glycolysis, malate-aspartate shuttle
(MAS) activity, and reverse Krebs cycle activity. The increased succinate concentrations
promote HIF-1a protein stabilization (via inhibition of the HIF hydroxylase enzymes),
driving optimal adaptation to hypoxia. In diabetic cells, increased fatty acids in hypoxia
inhibits anaerobic glycolysis, resulting in suppressed succinate concentrations and
decreased HIF-1a protein stabilization, blunting the adaptation to hypoxia.
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495mechanism to improve post-ischemic recovery in
type 2 diabetes. Type 2 diabetic rats were treated
in vivo long term with the HIF hydroxylase inhibitor
DMOG for 5 days, and after these 5 days, hearts were
isolated, perfused, and challenged with ischemia
(Figure 6). There were no differences in cardiac
function between groups at normal ﬂow or during
low-ﬂow ischemia. Untreated diabetic hearts had a
33% decrease in recovery of cardiac function
following reperfusion compared with controls. By
contrast, treating diabetic rats in vivo with DMOG
improved cardiac function by 46% compared with
untreated diabetic rats, restoring post-ischemic re-
covery to levels found in control hearts.
DISCUSSION
IR impairs cardiac HIF-1a activation during ischemia
and downstream adaptation to hypoxia. Here, we
demonstrate that this is mediated by FA-induced in-
hibition of HIF-1a protein accumulation. This is due
to increased targeting of HIF-1a for proteasomal
degradation by the regulatory HIF hydroxylases.
Mechanistically, this is mediated by decreased suc-
cinate concentrations from glycolytically driven
malate-aspartate shuttle activity, with succinate
supplementation restoring HIF-1a signaling in IR.
Finally, in vivo inhibition of the HIF hydroxylases
restores post-ischemic recovery of cardiac function in
diabetic rats.
Decreased HIF-1a protein accumulation was
evident in both diabetic hearts challenged with
ischemia, and in IR cardiomyocytes exposed to
hypoxia. HIF-1a plays a vital role in the survival of
cardiomyocytes following ischemia (2), and
decreased HIF activation post-ischemia has been
shown to accelerate the progression to heart failure
in genetic mouse models (1), thus failure to fully
activate HIF-1a in diabetic hearts would translate to
poorer long-term prognosis post-MI. FAs are the
predominant fuel used by the heart to power
contraction, accounting for 60% to 70% of cardiac
ATP generation. In diabetes, FA oxidation and
storage are up-regulated, and lipid intermediates
accumulate within the myocardium (14,15). The IR-
induced suppression of HIF-1a accumulation was
recapitulated by exposure to FAs. Palmitate and
oleate are both long-chain FAs; the former is satu-
rated and often implicated in oxidative damage and
apoptosis, whereas the latter is unsaturated and
does not induce these deleterious effects (32). Both
palmitate and oleate induced the same degree ofHIF-1a suppression and in a concentration-
dependent manner, demonstrating that this is a
conserved response between the 2 most abundant
FAs in blood. The relationship between FAs and HIF-
1a was further conﬁrmed pharmacologically using
the FA uptake inhibitor SSO, which was able to
restore HIF-1a accumulation in IR. This study shows
for the ﬁrst time that FAs can regulate HIF-1a sta-
bilization and downstream signaling, and although
we demonstrate this effect in type 2 diabetes, this
may also have relevance in any condition of
increased circulating lipids, for example, cardiovas-
cular disease, familial combined hyperlipidemia, or
starvation.
In normoxia, HIF-1a is translated and immediately
targeted for proteasomal degradation by a family of
HIF hydroxylases, which hydroxylate HIF making it a
substrate for destruction by the von Hippel-Lindau
ubiquitin-proteasome pathway. These HIF hydroxy-
lases, PHDs and FIH, use oxygen as their substrate,
thereby in hypoxia their activity is blunted, and HIF-
1a escapes hydroxylation and degradation, instead
migrating to the nucleus. IR did not modify HIF-1a
mRNA, demonstrating the inhibitory effect of FAs
was not mediated via changes in expression of this
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496transcription factor. Instead, HIF-1a protein in IR
could be rescued by inhibiting the proteasomal
degradation pathway or by additional pharmacolog-
ical inhibition of the HIF hydroxylases. These data
pointed towards the fact that (at 2% oxygen) the HIF
hydroxylases are inhibited by more than just low
oxygen but also by an additional factor, which was
absent in the IR cells.
The HIF hydroxylases are a-ketoglutarate–depen-
dent dioxygenases, which generate CO2 and succi-
nate as products of their reaction. In cancer cells,
mutations in Krebs cycle enzymes result in accu-
mulation of succinate, which via product inhibition
inhibits the HIF hydroxylases, causing HIF-1a accu-
mulation (30). Studies have shown that succinate
can inhibit the HIF hydroxylases to promote HIF-1a
accumulation, independently of oxygen concentra-
tion (24,30,33). In healthy hearts, myocardial succi-
nate levels increased 5-fold in response to acute
hypoxia (19), and others have shown that in
response to ischemia succinate levels increased 4-
fold (31). By contrast, we have shown previously
that in diabetic hearts, this hypoxia-induced succi-
nate accumulation was blunted (19). In the present
study, we demonstrate that this is due to FAs,
because culturing cells with palmitate or oleate
blunted succinate accumulation. This is further
reinforced by ﬁndings that pharmacologically sup-
pressing FA uptake in the diabetic heart increases
multiple metabolites within the second span of the
Krebs cycle (19), and restored HIF-1a accumulation.
Replenishing succinate was able to restore HIF-1a
accumulation in the presence of FAs, showing that
the inhibitory effect of FAs on HIF-1a accumulation
could be overcome. This signaling role for succinate,
linking metabolism to HIF regulation, occurs during
the hypoxic challenge, and provides a mechanism to
regulate the transcriptional response when oxygen is
chronically restricted. There has been growing in-
terest in the role of succinate, following its recog-
nition as a key driver of reperfusion injury via
reverse electron transport when oxygen supply is
reinstated (31). These 2 roles for succinate are not
mutually exclusive; when oxygen is limited, succi-
nate is playing an adaptive HIF signaling role, but
upon sudden restoration of oxygen the succinate is
rapidly reoxidized, removing this metabolite signal
(19) but with consequent effects on reactive oxygen
species generation (31).
At low oxygen, increased glycolysis is coupled to
increased malate-aspartate shuttle activity to
accommodate the increased cytosolic NADH (31).When oxygen availability is restricted, this mito-
chondrial malate is diverted backwards around the
Krebs cycle resulting in the generation of succinate
by reverse succinate dehydrogenase activity
(Figure 7) (31). Here, we demonstrate that inhibition
of any of these steps—glycolysis, malate-aspartate
shuttle activity, or succinate dehydrogenase activ-
ity—is able to suppress HIF-1a stabilization in hyp-
oxia. In the present study and previous ﬁndings, we
have shown that glycolysis and lactate efﬂux during
hypoxia are blunted by diabetes and insulin resis-
tance, facilitated by increased FA metabolism
(16,19,21). This is mediated by FA-induced Randle
cycle inhibition of key targets in glucose meta-
bolism, which can be overcome by blocking FA
metabolism (19,34). This FA-mediated decrease in
glycolysis would result in decreased cytosolic NADH
(35) and decreased malate-aspartate shuttle activity
(36) as reported by others.
Phase 3 clinical trials are currently underway using
HIF hydroxylase inhibitors for the treatment of ane-
mia. Here, we demonstrate that this pharmacological
approach, using the non-speciﬁc HIF hydroxylase
inhibitor DMOG, was able to stabilize HIF-1a in IR
cells, and improve recovery of cardiac function post-
ischemia in diabetic rats. Thus, by promoting HIF
stabilization and by overriding the inhibitory effect of
FAs on succinate, improvement in cardiac function
could be achieved.
CONCLUSIONS
IR prevents cardiac HIF-1a accumulation and down-
stream hypoxic adaptation in response to hypoxia.
This is mediated by elevated FAs in diabetes sup-
pressing succinate accumulation during hypoxia,
and increasing succinate concentrations can override
this inhibitory effect on HIF-1a stabilization. Phar-
macologically inhibiting the HIF hydroxylases pro-
motes HIF-1a accumulation and improves cardiac
function following ischemia-reperfusion in diabetic
rats.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Cardio-
vascular disease is the leading cause of death in patients
with type 2 diabetes, with increased mortality and
accelerated progression into heart failure following
myocardial infarction. A greater understanding of why
this occurs in diabetes and strategies to improve outcome
are needed. We report that the lipid-enriched metabolic
state of the diabetic heart prevents activation of the
master transcription factor hypoxia-inducible factor, and
the downstream adaptation to hypoxia needed for cardi-
omyocytes to survive in an ischemic/hypoxic environ-
ment. From a clinical standpoint, impaired activation of
hypoxic pathways in diabetes would contribute to
decreased recovery following a myocardial infarction.
TRANSLATIONAL OUTLOOK: For clinical translation,
these observations in cells and animal models should be
conﬁrmed at the tissue level in humans with and without
diabetes. Due to the exquisite oxygen sensitivity of
hypoxia-inducible factor, a challenge for this translation
will be how to obtain ischemic human tissue yet avoiding
re-oxygenation of the sample. Pharmacologically acti-
vating hypoxia-inducible factor following myocardial
infarction in diabetes is an exciting prospect from the
present data, given that similar compounds are under-
going phase III clinical trials for the treatment of anemia.
However, further basic research is required to conﬁrm
their repurposing for the diabetic heart.
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